Anindita De, Nagasamy Venkatesh, M Senthil, Bharat Kumar Reddy Sanapalli, R Shanmugham, Veera Venkata Satyanarayana Reddy Karri
{"title":"用于增强脑靶向性的替莫唑胺智能新体。","authors":"Anindita De, Nagasamy Venkatesh, M Senthil, Bharat Kumar Reddy Sanapalli, R Shanmugham, Veera Venkata Satyanarayana Reddy Karri","doi":"10.1177/1849543518805355","DOIUrl":null,"url":null,"abstract":"<p><p>Drug delivery to the brain is challenging because of the low permeability of blood-brain barrier, and therefore, optimum concentration of chemotherapeutics in the target area specifically for glioblastoma, an aggressive brain tumor, opens a new path of research. To achieve the goal, the oral alkylating agent temozolomide was incorporated into niosomes, and the surface was modified with chlorotoxin, a small 36 amino acid peptide discovered from the venom of scorpion <i>Leiurus quinquestriatus</i>. Active targeting using nanosized particles facilitates an increase in the accumulation of drugs in the cerebri by 3.04-folds. Temozolomide-loaded niosomes were prepared using conventional thin-film hydration method and characterized. Niosomes coated with chlorotoxin were produced with the size of 220 ± 1.45 nm with an entrapment efficiency of 79.09 ± 1.56%. Quantitative tissue distribution studies indicate enhanced permeation of the drug into the brain because of surface modification with less deposition in the highly perfused organs.</p>","PeriodicalId":56366,"journal":{"name":"Nanobiomedicine","volume":"5 ","pages":"1849543518805355"},"PeriodicalIF":0.0000,"publicationDate":"2018-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/e3/10.1177_1849543518805355.PMC6187422.pdf","citationCount":"0","resultStr":"{\"title\":\"Smart niosomes of temozolomide for enhancement of brain targeting.\",\"authors\":\"Anindita De, Nagasamy Venkatesh, M Senthil, Bharat Kumar Reddy Sanapalli, R Shanmugham, Veera Venkata Satyanarayana Reddy Karri\",\"doi\":\"10.1177/1849543518805355\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Drug delivery to the brain is challenging because of the low permeability of blood-brain barrier, and therefore, optimum concentration of chemotherapeutics in the target area specifically for glioblastoma, an aggressive brain tumor, opens a new path of research. To achieve the goal, the oral alkylating agent temozolomide was incorporated into niosomes, and the surface was modified with chlorotoxin, a small 36 amino acid peptide discovered from the venom of scorpion <i>Leiurus quinquestriatus</i>. Active targeting using nanosized particles facilitates an increase in the accumulation of drugs in the cerebri by 3.04-folds. Temozolomide-loaded niosomes were prepared using conventional thin-film hydration method and characterized. Niosomes coated with chlorotoxin were produced with the size of 220 ± 1.45 nm with an entrapment efficiency of 79.09 ± 1.56%. Quantitative tissue distribution studies indicate enhanced permeation of the drug into the brain because of surface modification with less deposition in the highly perfused organs.</p>\",\"PeriodicalId\":56366,\"journal\":{\"name\":\"Nanobiomedicine\",\"volume\":\"5 \",\"pages\":\"1849543518805355\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8b/e3/10.1177_1849543518805355.PMC6187422.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nanobiomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/1849543518805355\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Engineering\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanobiomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1849543518805355","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Engineering","Score":null,"Total":0}
Smart niosomes of temozolomide for enhancement of brain targeting.
Drug delivery to the brain is challenging because of the low permeability of blood-brain barrier, and therefore, optimum concentration of chemotherapeutics in the target area specifically for glioblastoma, an aggressive brain tumor, opens a new path of research. To achieve the goal, the oral alkylating agent temozolomide was incorporated into niosomes, and the surface was modified with chlorotoxin, a small 36 amino acid peptide discovered from the venom of scorpion Leiurus quinquestriatus. Active targeting using nanosized particles facilitates an increase in the accumulation of drugs in the cerebri by 3.04-folds. Temozolomide-loaded niosomes were prepared using conventional thin-film hydration method and characterized. Niosomes coated with chlorotoxin were produced with the size of 220 ± 1.45 nm with an entrapment efficiency of 79.09 ± 1.56%. Quantitative tissue distribution studies indicate enhanced permeation of the drug into the brain because of surface modification with less deposition in the highly perfused organs.
NanobiomedicineBiochemistry, Genetics and Molecular Biology-Biotechnology
CiteScore
6.80
自引率
0.00%
发文量
1
审稿时长
14 weeks
期刊介绍:
Nanobiomedicine is an international, peer-reviewed, open access scientific journal that publishes research in nanotechnology as it interfaces with fundamental studies in biology, as well as its application to the fields of medicine. Nanobiomedicine covers all key aspects of this research field, including, but not limited to, bioengineering, biophysics, physical and biological chemistry, and physiology, as well as nanotechnological applications in diagnostics, therapeutic application, preventive medicine, drug delivery, and monitoring of human disease. Additionally, theoretical and modeling studies covering the nanobiomedicine fields will be considered. All submitted articles considered suitable for Nanobiomedicine are subjected to rigorous peer review to ensure the highest levels of quality. The review process is carried out as quickly as possible to minimize any delays in the online publication of articles. Submissions are encouraged on all topics related to nanobiomedicine, and its clinical applications including but not limited to: Nanoscale-structured biomaterials, Nanoscale bio-devices, Nanoscale imaging, Nanoscale drug delivery, Nanobiotechnology, Nanorobotics, Nanotoxicology, Nanoparticles, Nanocarriers, Nanofluidics, Nanosensors (nanowires, nanophotonics), Nanosurgery (dermatology, gastroenterology, ophthalmology, etc), Nanocarriers commercialization of nanobiomedical technologies, Market trends in the nanobiomedicine space, Ethics and regulatory aspects of nanobiomedicine approval, New perspectives of nanobiomedicine in clinical diagnostics, BioMEMS, Nano-coatings, Plasmonics, Nanoscale visualization.